Evidence map›Paper›PMID 39441479›Full record

ReviewCurrent oncology reports2024

Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma.

Margaret C Wheless, Margaret Comer, Michael K Gibson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Margaret C WhelessDepartment of Medicine, Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Margaret ComerVanderbilt University Medical School, Nashville, TN, USA.
Michael K GibsonDepartment of Medicine, Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. Mike.gibson.1@vumc.org.

Funding

VOLT (Vanderbilt Oncology Training Program)T32CA217834 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Douglas B Johnson · 2018 to 2026
$2.7M
NCI NIH HHS T32 CA217834
6 · The paper itself

Abstract

purpose of reviewThis review highlights advances and recent changes in the treatment paradigm for advanced esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (GEJAC). RECENT

findingsChemotherapy remains the backbone of treatment for advanced EAC/GEJAC. New targets/agents include immunotherapy, HER-2, claudin18.2, and FGFR2b, with various mechanisms (CAR-T, bispecific mAB, ADCs) altering the treatment landscape against these targets. The approaches to these targets may act together, in sequence, and even synergistically to improve outcomes. Herein, we review the state of the field, including highlighting ongoing clinical trials and additional emerging agents and approaches.

Indexed as

AdenocarcinomaEsophageal NeoplasmsEsophagogastric JunctionStomach NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansImmunotherapyMolecular Targeted TherapyErb-b2 Receptor Tyrosine KinasesClaudin18.2Esophageal AdenocarcinomaFGFRGastroesophageal Junction AdenocarcinomaHER-2PD-L1 Therapy

Identifiers

PMID39441479
PMCPMC11579124

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.